c1 - transparency - shum - salon b

Transparency in the Evaluation & Funding Process

How far can we go?

David Shum, PharmD, MBA

Director, Reimbursement & Health Economics

Roche Pharmaceuticals

2013 CADTH Symposium

St. John’s, NL

May 6, 2013

Increasing focus on transparency issues

Ref: Google ngram viewer

1900 1950 2000

‘‘committed to transparency’’- US delegation (NYT, March 2013)

‚supersecretive in one part about our products…but there are other areas where we will be completely transparent‛

Source: BusinessWeek, Dec 2012

Source: FT, April 2013

Transparency Index across HTA countries

Ref: Roche data

Fair & open process

Principles: priority setting

Patient / stakeholders

CCI

Patient data

Resources

Government

Information should be exempt from the general rule of public access

Disclosure of information would prejudice their economic interest

‚any prejudice to the Ministry’s economic interest in this regard has a repercussive, concomitant negative impact on the government’s financial interest…‛

Industry

Information should be exempt from the general rule of public access

Commercial information - confidential business tactics, strategies, and plans

• Positive steps to increasing

transparency in trial data and

HTA

• Tradeoffs between total

transparency and opacity

Towards increasing transparency

We Innovate Healthcare